Navigation Links
Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Date:6/2/2008

nations of two or more direct antivirals. It is expected that the next generation of therapies for treatment of HCV will include small molecules, such as ANA598, that act directly upon specific viral enzymes to inhibit viral replication. These direct antivirals are expected to improve overall therapy by increasing cure rates and improving tolerability and convenience of treatment.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist prodrug for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the planned trial design of the ANA598 healthy volunteer study; (ii) Anadys' expectation to begin a Phase Ib study of ANA598 in the third quarter of 2008; (iii) Anadys' belief that ANA598 has the potential to become an important component of future combination therapy for patients with HCV infection and that the full benefit of direct antivirals will be demonstrated when studied as components of novel combination regimens incorporating multiple anti-HCV agents; (iv) Anadys' ability to achieve important clinical milestones in the ANA598 and ANA773 programs; and (v) expectations regarding the evolution of the market for HCV therapies. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anad
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)...  Cancer Treatment Institute of Colombia ... treatment: a carefully formulated, first-of-its-kind combination of salinomycin ... at treating multiple types of cancer. The team ... optimistic that it could significantly improve outcomes for ... "These two drugs are exceptional on ...
(Date:9/29/2014)... 2014 Apexus, LLC, the prime vendor ... that it has been selected by the Health ... in its role as the prime vendor through ... position for the past 10 years, will continue ... locations, drug manufacturers, pharmacy wholesalers, and other stakeholders ...
(Date:9/29/2014)... , Sept. 29, 2014  Guerbet, a ... medical imaging, has received a Drug Shortage Assistance ... for its assistance in preventing or alleviating a ... for its efforts related to the shortage of ... drug application, submitting several post-approval supplements to restart ...
Breaking Medicine Technology:Cancer Treatment Institute of Colombia Demonstrates Unprecedented Results Using Unique Cancer Drug Combination of 3-Bromopyruvate and Salinomycin for Treatment of Multiple Types of Cancer 2Cancer Treatment Institute of Colombia Demonstrates Unprecedented Results Using Unique Cancer Drug Combination of 3-Bromopyruvate and Salinomycin for Treatment of Multiple Types of Cancer 3Apexus Wins HRSA Contract to Remain Prime Vendor of 340B Program 2Guerbet Receives FDA's Drug Shortage Assistance Award: Recognized for contributions to address a shortage of Ethiodol (ethiodized oil) injection 2
... honor of National Women,s Health Week, Someone With ... home health and medical supply online storefront, www.someonewith.com , ... catalog solutions for more than 2.5 million breast cancer survivors ... women who will be diagnosed with breast cancer this year. ...
... (NYSE Amex: ANX ) today reported financial results ... "We are pleased to have completed the acquisition of SynthRx ... to reach agreement on the protocol for a pivotal phase ... crisis," said Brian M. Culley, Chief Executive Officer of ADVENTRX. ...
Cached Medicine Technology:Someone With Opens its Doors to Create Online Marketplace for Breast Cancer Products and Services 2Someone With Opens its Doors to Create Online Marketplace for Breast Cancer Products and Services 3Someone With Opens its Doors to Create Online Marketplace for Breast Cancer Products and Services 4ADVENTRX Reports First Quarter 2011 Financial Results 2ADVENTRX Reports First Quarter 2011 Financial Results 3ADVENTRX Reports First Quarter 2011 Financial Results 4ADVENTRX Reports First Quarter 2011 Financial Results 5
(Date:9/30/2014)... In honor of National Breast Cancer Awareness ... courageous battles, Incredible Veins, Body & Skin is offering ... Cynosure. , “For cancer patients who receive radiation ... on their skin to accurately aim the radiation on ... survivors, they decide to have their tattoo removed as ...
(Date:9/30/2014)... Every New Year begins with a Resolution that will soon ... of effort, however most are out of mind in 30. Why? ... Instead of "spend more time with children", try something easy to ... Without a reminder, daily life gets in the way and efforts ... 3. Goals out of sight equals goals out of mind. ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 From October ... be exhibiting at the 2014 SHSMD Connections Annual Conference ... for Healthcare Strategy & Market Development (SHSMD) is proud ... marketing, public relations and communications, and strategic planning professionals ... About SHSMD Connections , The conference is a ...
(Date:9/30/2014)... Albany, IN (PRWEB) September 30, 2014 ... Dr. Ron Receveur encourages all persons who have received ... disease in a recent blog post. , The post, ... those with dental implants that if they don’t brush ... the same way people lose their natural teeth: the ...
(Date:9/30/2014)... Chicago, IL (PRWEB) September 30, 2014 ... cannabinoid clash,” opened Bryan W. Brickner, “and it’s ... Sleep Political Cannabinoid Science , new on the ... sleep research from the National Institutes of Health ... articles regarding: de-homeostatic sleep disturbances, REM transitions, aging ...
Breaking Medicine News(10 mins):Health News:Incredible Veins, Body & Skin Takes A Stand Against Breast Cancer With PicoSure® By Cynosure 2Health News:MMS, Inc. (Medical Marketing Service) to Attend the 2014 SHSMD Connections Annual Conference in October 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2
... at Children,s National Medical Center and the ... the results of the first successful application of "multiple ... muscular dystrophy in an animal larger than a ... "DNA band-aids" to skip over the parts of the ...
... SAN DIEGO, March 16 Gen-Probe Incorporated (Nasdaq: ... (AIM: TED) approved the acquisition of Tepnel by Gen-Probe by ... London earlier today.More than 99% of Tepnel shareholders voted in ... 30, 2009 and is structured as a "scheme of arrangement" ...
... Office Building Project Provides State-of-the-Art Healthcare for Rural ... Roads Ventures (HRV), a community development investment firm, ... program to provide equity and debt financing for ... rural communities in Virginia providing successful solutions to ...
... products contain allergens no matter what ingredients are listed, study ... number of food products with a "may contain" label actually ... of foods products without such a claim also contain allergens, ... came from smaller companies, noted the authors of a study ...
... March 16 /PRNewswire-Asia-FirstCall/ -- China Yongxin Pharmaceuticals, Inc. ... Board: CYXN), a leading manufacturer, distributor and retailer ... it has rolled out its Electronic Diagnosis System ... Changchun, Jilin. In order to ensure safety of ...
... adventure series results from a life of creative ... Ohio, March 16 Randy Patterson has spent ... a deadly, aggressive and extremely rare cancer called ... nine grueling spinal taps, mounting financial debt, and ...
Cached Medicine News:Health News:First treatment for muscular dystrophy in sight: Scientists successfully harness exon-skipping 2Health News:First treatment for muscular dystrophy in sight: Scientists successfully harness exon-skipping 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 2Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 3Health News:Tepnel Shareholders Approve Acquisition by Gen-Probe 4Health News:Hampton Roads Ventures Tackles U.S. Healthcare Crisis Community by Community 2Health News:Food Allergy Labeling Not Always Accurate 2Health News:Food Allergy Labeling Not Always Accurate 3Health News:China Yongxin Pharmaceuticals Inc. Launches Electronic Diagnosis System in its Changchun Drugstores 2Health News:China Yongxin Pharmaceuticals Inc. Launches Electronic Diagnosis System in its Changchun Drugstores 3Health News:Trinadgey Launches to Sci-Fi Lovers via New Online Portal Trinadgey.com 2
... The patented ratchet design provides fingertip ratchet ... Series I Instrument program offers state-of-the-art quality ... while maintaining strength and durability. Low profile ... tight joint spaces. Series I instruments are ...
... procedurally specific tip configurations provide maximum ... to all areas of the meniscus ... Graspers feature an infinite position sliding-lock ... tearing or slipping even in ...
Smith & Nephew ACUFEX scissors are constructed without pins for maximum strength, dependability, durability, and safety.,A wide range of tips and angles enable the surgeon to effectively dissect any ...
The most traditional style of instrument, a classical punch shape with the parrot beak upper jaw to aid in the capture of tissue....
Medicine Products: